CTI Begins Enrollment in Phase 3 PERSIST-1 Trial of Pacritinib

News   Jan 10, 2013

 
CTI Begins Enrollment in Phase 3 PERSIST-1 Trial of Pacritinib
 
 
 

RELATED ARTICLES

DataArt Joins Biotechnology Association BIO Deutschland

News

Global technology consultancy DataArt announced today that it has joined BIO Deutschland, Germany's biotechnology industry association.

READ MORE

Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to Treatment

News

Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.

READ MORE

BC Platforms Announces Collaborations in Multiple Sclerosis Research

News

Company's technology and research platforms used to better understand genetic basis of MS.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE